The Fund aims to achieve long term capital growth primarily through investment in a focussed portfolio of equities issued by companies established in any country and in derivatives, the underlying assets of which are equities issued by companies established in any country.
Name | % Net Assets |
---|---|
Altria Group Inc. | 2.3% |
Sanofi-Synthelabo | 2.2% |
British American Tobacco | 2.1% |
Anheuser-Busch Inbev | 2.1% |
CBS Corp | 2.0% |
Amerisourcebergen Corp. | 2.0% |
Telstra Corp. Ltd. | 2.0% |
Unitedhealth Group Inc. | 2.0% |
Novartis | 2.0% |
Oracle Corp. | 2.0% |
Key | % Net Assets |
---|---|
Altria Group Inc. | 2.3% |
Sanofi-Synthelabo | 2.2% |
British American Tobacco | 2.1% |
Anheuser-Busch Inbev | 2.1% |
Other | 91.3% |
Date | 07-Oct-2022 |
---|---|
NAV | $2.17 |
Currency | USD |
Change | $0.01 |
% | 0.44% |
YTD change | $2.17 |
YTD % | n/a |
Fund Inception | 24/02/1998 |
---|---|
Fund Manager | Jacob Robbins |
TER | 1.62 (28-Feb-2012) |
Minimum Investment | |
---|---|
Initial | $100000 |
Additional | $500 |
Savings | $100 |
Charges | |
---|---|
Initial | 4.50% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | -0.01 |
You are here: research